Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
Otto Metzger(Dana-Farber Cancer Institute), Daniel G. Stover(The Ohio State University), Michael Untch(Helios Hospital Berlin-Buch), Mark A. Watson(Washington University in St. Louis), Peter Ansell(AbbVie (United States)), Carsten Denkert(Philipps University of Marburg), William M. Sikov(Providence College), Katharine A. Collier(The Ohio State University), Norman Wolmark(NSABP Foundation), David Maag(AbbVie (United States)), Lijun Cheng(Taizhou Central Hospital), Charles E. Geyer(Houston Methodist), Junu Bae(The Ohio State University), Jens Huober, Joyce O’Shaughnessy(Texas Oncology), Mathew Cherian(The Ohio State University), Sibylle Loibl, Sarah Asad(The Ohio State University), Hope S. Rugo(University of California, San Francisco), Lang Li(The Ohio State University), Gϋnter von Minckwitz(German Breast group), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Mehra Golshan, Priya Rastogi(UPMC Hillman Cancer Center)
Cited by 37
Related Papers
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
|New England Journal of Medicine|2005|5.3k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k